A Study Of Effect Of Secretin For In Injection (Chirostim) On Pancreatic Fluid Composition In Healthy Subjects
Part of paid clinical trials in Rochester, Minnesota.
- Sponsor
- Mayo Clinic
- Study ID
- NCT07285863
- Phase
- PHASE4
- Status
- Recruiting
Conditions
- Chronic Pancreatitis
- Exocrine Pancreatic Insufficiency
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - 80 Years
- Healthy Volunteers
- Accepted
Interventions
- Secretin (human synthetic) - ChiRhoClin — DRUGDuring endoscopic ultrasound (EUS), a dose of intravenous secretin (0.2 µg/kg) will be administered over the course of 1 minute to stimulate pancreatic ductal cells to secrete pancreas fluid. Duodenal fluid will be aspirated through the echoendoscope in 5 minute increments (5, 10, 15, and 20 minutes) after the secretin has been administered
Study Details
The purpose of this study is to collect pancreas fluid from the duodenum using the endoscopic pancreas function collection method in healthy participants after pancreatic stimulation with human secretin.
Key Dates
- Start date
- Mar 11, 2026
- Status verified
- Apr 2026
- Primary completion
- Mar 31, 2027
- Completion
- Mar 31, 2028
Study Design
- Enrollment
- 24 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- OTHER
Arms
- Experimental: Healthy ParticipantsHealthy participants without pancreatic disease who are undergoing an endoscopic ultrasound for a non-pancreatic indication. This arm will be stratified into 3 age groups: 18-35, 35-45, and 46+ years. Participants will be given a standard dose of intravenous human secretin (0.2 mcg/kg) during the endoscopic ultrasound. During this time, pancreatic fluid will be collected at 5 minutes, 10 minutes, 15 minutes, and 20 minutes after secretin administration.
Primary Outcome Measure
Pancreatic Fluid Bicarbonate Composition [ Time Frame: 5, 10, 15, and 20-minutes post-secretin administration ]
Central Contacts
- Liz Lemke507-266-3317
- Samuel Han, MD
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Mayo Clinic in Rochester | Rochester | Minnesota | 55905 | Liz Lemke 507-266-3317 Samuel Han, MD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Rochester, MN
By research site
Related Studies
- Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic DisordersRecruiting · Mayo Clinic · Phoenix, Arizona
- Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)Recruiting · M.D. Anderson Cancer Center · Los Angeles, California
- Pancreatic Enzyme Replacement Therapy for Acute Pancreatitis-Associated Exocrine Pancreatic InsufficiencyPHASE4 · Recruiting · Ohio State University · Los Angeles, California
- Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 StudyRecruiting · M.D. Anderson Cancer Center · Los Angeles, California